ANI Pharmaceuticals (ANIP) Stock: Revenue Jumps 44% as Rare Disease Pipeline Transforms Outlook

TLDR

• Q4 revenue jumped 29.6% to $247.1M as rare disease sales surged.
• Cortrophin hit $111.4M in Q4 as demand widened across specialties.
• ILUVIEN added $19.8M as coverage gains improved patient access.
• Generics rose 28.2% to $100.8M, powered by launches and partners.
• 2026 outlook: $1.06–$1.12B revenue and up to $290M adjusted EBITDA.

ANI Pharmaceuticals (ANIP) shares posted strong fourth-quarter momentum as revenue and earnings advanced sharply across key product segments. The stock closed at $77.15 and climbed to $78.68 in pre-market trading. The company delivered record full-year revenue and expanded its position in the rare disease market.

ANI Pharmaceuticals, Inc., ANIP

Rare Disease Performance Strengthens Growth Outlook

ANI Pharmaceuticals reported quarterly rare disease revenue of $131.3 million and the segment expanded 50.8% from the prior year. Cortrophin Gel drove most of the increase as net revenue reached $111.4 million for the quarter. ILUVIEN added $19.8 million and supported broader market access efforts.

Cortrophin Gel maintained strong demand as usage widened across neurology, rheumatology, nephrology and ophthalmology. Prescribing for acute gouty arthritis flares continued to rise and represented more than 15% of total use. The planned expansion of the rare disease organization aims to capture additional opportunities in mid-2026.

ILUVIEN advanced through improved coverage and commercial activity. Strategic investments supported increased patient access and strengthened uptake across its indications. The company expects continued gains as expanded channels mature.

Generics Segment Builds Scale With New Launches

The generics segment reported quarterly revenue of $100.8 million and grew 28.2% year over year. A partnered launch that began in the third quarter helped drive the improvement. Additional products introduced in 2025 also supported the expansion.

Royalty revenue declined due to lower contributions from certain services.  Overall segment performance reflected operational strength across the generics platform. The company continues to advance a steady rhythm of new product introductions.

Brand revenue decreased to $12.3 million due to normalization in demand for select products. The decline aligned with expected patterns following prior periods of elevated sales. The company remains focused on supporting stable performance in this segment.

Financial Results Highlight Broad Margin and Earnings Gains

Total quarterly revenue reached $247.1 million and increased 29.6% from the prior year. Gross margin improved on a GAAP basis due to the absence of prior purchase accounting costs. Non-GAAP margin eased as higher royalty-bearing product sales shifted the mix.

Operating expenses increased due to higher employment costs and expanded rare disease and ophthalmology infrastructure. Research and development costs decreased because of timing adjustments for ongoing programs. The company continued to invest in programs that support future growth.

Quarterly net income reached $27.5 million and marked a sharp turnaround from the prior year loss. Adjusted diluted earnings per share rose to $2.33 as revenue and margin expansion lifted results. Adjusted EBITDA increased to $65.4 million and grew 30.6%.

2026 Guidance Reinforces Multi-Year Expansion Plan

ANI Pharmaceuticals reaffirmed its 2026 outlook with projected revenue between $1.055 billion and $1.115 billion. Cortrophin Gel is expected to generate up to $575 million as new specialty and primary care efforts scale. ILUVIEN revenue should reach up to $83 million.

The company expects adjusted EBITDA to rise up to $290 million, reflecting continued margin strength. EPS guidance indicates further improvement as operating leverage expands. ANI closed 2025 with strong liquidity and generated $185.2 million in operating cash flow.

The company aims to transform into a leading rare disease entity while maintaining disciplined execution in generics and brand operations.

The post ANI Pharmaceuticals (ANIP) Stock: Revenue Jumps 44% as Rare Disease Pipeline Transforms Outlook appeared first on CoinCentral.